Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Methyldopa

FDA-approved product (tablet, oral), marketed as Aldomet, Methyldopa.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Methyldopa
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Methyldopa
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA21.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli28.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae8.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Methyldopa in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Methyldopa with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants

    NCT07442591 · start 2026-03-24

    Registered record
    Registry ID
    NCT07442591
    Conditions
    Healhty
    Interventions
    Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg); Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg); Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-03-24
    Completion
    2026-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealhty
    InterventionCarbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg); Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg); Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)
    PhasePhase 1
    Registry statusRecruiting

  • Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease

    NCT07151378 · start 2025-10-27

    Registered record
    Registry ID
    NCT07151378
    Conditions
    PARKINSON DISEASE (Disorder)
    Interventions
    LECIG (levodopa, carbidopa, entacapone intestinal gel); Best oral medication
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-10-27
    Completion
    2030-09-22
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPARKINSON DISEASE (Disorder)
    InterventionLECIG (levodopa, carbidopa, entacapone intestinal gel); Best oral medication
    PhasePhase 3
    Registry statusRecruiting

  • Effect of Pilates Exercise Versus Circuit Exercise Training on Gestational Hypertension

    NCT06618521 · start 2024-09-30

    Registered record
    Registry ID
    NCT06618521
    Conditions
    Gestational Hypertension
    Interventions
    Anti-hypertensive drug (Methyldopa 250 mg); Pilates exercise; Circuit exercise training
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-09-30
    Completion
    2025-10-31
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGestational Hypertension
    InterventionAnti-hypertensive drug (Methyldopa 250 mg); Pilates exercise; Circuit exercise training
    PhaseNot applicable
    Registry statusCompleted

  • Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in the Postprandial State in Healthy Chinese Subjects

    NCT06180720 · start 2023-12-20

    Registered record
    Registry ID
    NCT06180720
    Conditions
    Healthy
    Interventions
    Test (T) Entacapone,Levodopa and Carbidopa Tablets (II); Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2023-12-20
    Completion
    2024-11-20
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTest (T) Entacapone,Levodopa and Carbidopa Tablets (II); Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)
    PhasePhase 1
    Registry statusUnknown

  • A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

    NCT06161220 · start 2023-10-30

    Registered record
    Registry ID
    NCT06161220
    Conditions
    Cardiac Repolarization in Healthy Subjects
    Interventions
    Carbidopa capsule; Moxifloxacin Tablets, USP; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-10-30
    Completion
    2023-12-05
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Repolarization in Healthy Subjects
    InterventionCarbidopa capsule; Moxifloxacin Tablets, USP; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in Healthy Chinese Subjects

    NCT05976737 · start 2023-08-17

    Registered record
    Registry ID
    NCT05976737
    Conditions
    Healthy
    Interventions
    Test (T) Entacapone,Levodopa and Carbidopa Tablets (II); Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2023-08-17
    Completion
    2024-07-12
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTest (T) Entacapone,Levodopa and Carbidopa Tablets (II); Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)
    PhasePhase 1
    Registry statusUnknown

  • Effect of Foot Reflexology on Preeclampsia

    NCT05888896 · start 2023-06-09

    Registered record
    Registry ID
    NCT05888896
    Conditions
    Mild Pre-eclampsia
    Interventions
    methyldopa tablets 250mg; methyldopa tablets 250mg + foot reflexology
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-06-09
    Completion
    2023-09-20
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild Pre-eclampsia
    Interventionmethyldopa tablets 250mg; methyldopa tablets 250mg + foot reflexology
    PhaseNot applicable
    Registry statusUnknown

  • Prevalence of High Plasmatic 3OMethyldopa Level in a Specific Population of Patients With a Symptomatology Compatible With AADC Deficiency

    NCT05211609 · start 2022-05-20

    Registered record
    Registry ID
    NCT05211609
    Conditions
    Aromatic L-Amino Acid Decarboxylase Deficiency
    Interventions
    Plasmatic 3-O-Methyldopa dosage
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-05-20
    Completion
    2024-11-01
    Enrolment
    388

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAromatic L-Amino Acid Decarboxylase Deficiency
    InterventionPlasmatic 3-O-Methyldopa dosage
    PhaseNot applicable
    Registry statusUnknown

  • Bioavailability of Levodopa 250 mg and Carbidopa 25 mg With Regards to Reference Product

    NCT05250141 · start 2022-02-14

    Registered record
    Registry ID
    NCT05250141
    Conditions
    Bioequivalence
    Interventions
    Levodopa 250mg and Carbidopa 25mg Test Drug tablet; Levodopa 250mg and Carbidopa 25mg Referent Product tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-02-14
    Completion
    2022-02-17
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioequivalence
    InterventionLevodopa 250mg and Carbidopa 25mg Test Drug tablet; Levodopa 250mg and Carbidopa 25mg Referent Product tablet
    PhasePhase 1
    Registry statusCompleted

  • Histaminergic Basis of Fatigue in Multiple Sclerosis

    NCT04764383 · start 2022-01-01

    Registered record
    Registry ID
    NCT04764383
    Conditions
    Multiple Sclerosis
    Interventions
    L-Histidine; Placebo; Lodosyn
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2022-01-01
    Completion
    2022-10-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionL-Histidine; Placebo; Lodosyn
    PhasePhase 2
    Registry statusWithdrawn

  • Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients

    NCT04778176 · start 2021-06-16

    Registered record
    Registry ID
    NCT04778176
    Conditions
    Parkinson's Disease
    Interventions
    continuous oral delivery of levodopa/carbidopa
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-06-16
    Completion
    2022-08-02
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    Interventioncontinuous oral delivery of levodopa/carbidopa
    PhasePhase 2
    Registry statusCompleted

  • Management of Hypertension in the Early Postpartum: a Randomized Controlled Trial

    NCT04835233 · start 2021-05-01

    Registered record
    Registry ID
    NCT04835233
    Conditions
    Pregnancy-Induced Hypertension in Postpartum; Postpartum Pre-Eclampsia; Hypertension
    Interventions
    Methyldopa 250 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-05-01
    Completion
    2022-12-31
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnancy-Induced Hypertension in Postpartum; Postpartum Pre-Eclampsia; Hypertension
    InterventionMethyldopa 250 MG
    PhasePhase 4
    Registry statusCompleted

  • Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

    NCT04325503 · start 2021-02-08

    Registered record
    Registry ID
    NCT04325503
    Conditions
    Parkinsonian Signs in Older Persons
    Interventions
    carbidopa
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2021-02-08
    Completion
    2022-06-30
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinsonian Signs in Older Persons
    Interventioncarbidopa
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes

    NCT03396484 · start 2020-09

    Registered record
    Registry ID
    NCT03396484
    Conditions
    Type1 Diabetes Mellitus
    Interventions
    Methyldopa; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2020-09
    Completion
    2022-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType1 Diabetes Mellitus
    InterventionMethyldopa; Placebo
    PhasePhase 2
    Registry statusWithdrawn

  • Vigor and the LDR in Parkinson Disease

    NCT04821830 · start 2020-02-12

    Registered record
    Registry ID
    NCT04821830
    Conditions
    Parkinson Disease
    Interventions
    carbidopa/levodopa, as prescribed by treating physician
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-02-12
    Completion
    2024-04-25
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    Interventioncarbidopa/levodopa, as prescribed by treating physician
    PhasePhase 4
    Registry statusCompleted